Apolipoprotein E in Alzheimer's disease risk and case detection: A case-control study

Journal of Clinical Epidemiology

Volumn 49, Issue 10, 1996, Pages 1143-1148

  Kukull, Walter A ^a   Schellenberg, Gerard D ^b   Bowen, James D ^a   McCormick, Wayne C ^a   Yu, Chang En ^a   Teri, Linda ^a   Thompson, Jill D ^a   O'Meara, Ellen S ^a   Larson, Eric B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; APOE; Dementia; Diagnosis; Genetic risk factors; Screening

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; COGNITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICAL RECORD; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST;

EID: 0030273357     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-4356(96)00195-3     Document Type: Article

References (42)

1. 1. Bird TD, Sumi SM, Nemens EJ, Nochlin D, Schellenberg G, Lampe TH, et al. Phenotypic heterogeneity in familial Alzheimer's disease: A study of 24 kindreds. Ann Neurol 1989; 25: 12-25.
2. 2. Schellenberg GD, Bird TD, Wijsman EM, Moore DK, Boehnke M, Bryant EM, et al. Absence of linkage of chromosome 21q21 marker to familial Alzheimer's disease. Science 1988; 241: 1507-1510.
3. 3. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of missense mutation in the amyloid precursors protein gene with familial Alzheimer's disease. Nature (London) 1991; 349: 704-706.
4. 4. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258: 668-671.
5. 5. Schellenberg G, Deeb SS, Boehnke M, Bryant EM, Martin GM, Lampe TH, et al. Association of apolipoprotein CII allele with familial dementia of the Alzheimer's type. J Neurogenet 1987; 4: 97-108.
6. 6. Schellenberg G, Boehnke M, Wijsman E, Moore D, Martin G, Bird T. Genetic association and linkage analysis of apolipoprotein CII locus and familial Alzheimer's disease. Ann Neurol 1992; 31: 223-227.
7. 7. Pericak-Vance MA, Bebout JL, Gaskell Jr, PC, Yamaoka LH, Hung WY, Alberts MJ, et al. Linkage studies in familial Alzheimer' disease: Evidence for chromosome 19 linkage. Am J Hum Genet 1991; 48: 1034-1050.
8. 8. Houlston RS, Snowden C, Green F, Alberti KGMM. Apolipoprotein (apo) E genotypes by polymerase chain reaction and allele-specific oligonucleotide probes: No detectable disequilibrium between ApoE and ApoCII. Hum Genet 1989; 83: 364-368.
9. 9. Strittmatter W, Wesgraber K, Huang D, Dong LM, Salveson GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid (beta) peptide: Isoform-specific effects and implications for late-onset Alzheimer's disease. Proc Natl Acad Sci. 1993; 90: 8098-8102.
10. 10. Corder E, Saunder A, Strittmatter W, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
11. 11. Mayeux R, Stern Y, Ottman R, Tatemichi TK, Ming-Xin Tang, Maestre G, et al. The apolipoprotein e4 allele in patients with Alzheimer's disease. Ann Neurol 1993; 34: 752-754.
12. 12. Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele (epsilon) 4 with late onset Aizheimer's disease. Neurology 1993; 43: 1467-1472.
13. 13. Tsai MS, Tangalos EG, Petersen RC, Smith GE, Shaid DJ, Kokmen E, et al. Apolipoprotein E: Risk factor for Alzheimer's disease. Am J Hum Genet 1994; 54: 643-649.
14. 14. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid forming diseases. Lancet 1993; 342: 710-711.
15. 15. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697-699.
16. 16. Ueki A, Kawano M, Namba Y, Kawakami M, Ikeda K. A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late onset nonfamilial Alzheimer's disease. Neurosci Lett 1993; 163: 166-168.
17. 17. Brousseau T, Legrain S, Berr C, Bourlet V, Vidal O. Confirmation of the epsilon 4 allele of apolipoprotein E gene as a risk factor for late onset Alzheimer's disease. Neurology 1994; 44: 342-344.
18. 18. Peacock ML, Fink JK. ApoE epsilon 4 allelic association with Alzheimer's disease: Independent confirmation using denaturing gradient gel electrophoresis. Neurology 1994; 44: 339-341.
19. 19. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset AD. Nat Genet 1994; 7: 180-183.
20. 20. vanDuijn CM, DeKniff P, Cruts M, Wehnert A, Havekes LM, Hofman, et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimzer's disease. Nat Genet 1994; 7: 74-78.
21. 21. Yu CE, Payami H, Olson JM, Boehnke M, Wijsman EM, Orr HT, et al. The apolipoprotein E/CI/CII gene cluster and late onset Alzheimer's disease. Am J Hum Genet 1994; 54: 631-642.
22. 22. Salo MK, Rantanen R, Huupponen T, Lehtimaki T, Jokela H. Apolipoprotein E phenotypes and plasma lipids in diabetic children and adolescents. Eur J Pediatr 1993; 152: 564-568.
23. 23. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet 1992; 340: 879-880.
24. 24. Katzel LI, Fleg JL, Paidi M, Ragoobarsingh N, Goldberg AP. ApoE4 polymorphism increases risk for exercise-induced silent myocardial ischemia in older men. Arterioscler Thromb 1993; 13: 1495-1500.
25. 25. Yamamura T, Dong LM, Yamamoto A. Apolipoprotein E polymorphism and coronary heart disease. Chin Med J Engl 1992; 105: 738-741.
26. 26. Schacter F, Faure-Delanef L, Guenot F, Fouger H, Frogeul P, Lesueur-Ginot L, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994; 6: 29-32.
27. 27. Cauley JA, Eichner JE, Kamboh MI, Ferrell RE, Kuller LH. Apo E allele frequencies in younger (age 42-50) vs older (age 65-90) women. Genet Epidemiol 1993; 10: 27-34.
28. 28. Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglund L. Apolipoprotein E polymorphism in a healthy Swedish population: Variation of allele frequency with age in relation to serum lipid concentrations. Clin Chem 1993; 39: 2125-2129.
29. 29. Kervinen K, Savolainen MJ, Salokannel J, Hynninen A, Heikkinen J, Ehnholm C, et al. Apolipoprotein E and B polymorphisms - longevity factors assessed in nonagenarians. Atherosclerosis 1994; 105: 89-95.
30. 30. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Julette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype and late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 9649-9653.
31. 31. Wisneiwski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: Binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 1993; 192: 359-365.
32. 32. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interaction. Neuron 1993; 11: 575-580.
33. 33. McKhann G, Drachman D, Folstein U, Katzman R, Price D, Stadlan E. Clinical diagnoses of Alzheimer's disease: Report of the NINCDS/ ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
34. 34. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. (revised). Washington, D.C.: American Psychiatric Association; 1987.
35. 35. Larson EB, Kukull WA, Teri L, McCormick W, Pfanschmidt M, vanBelle G, et al. The University of Washington Alzheimer's Disease Patient Registry (ADPR) 1987-1988. Aging 1990; 2: 404-408.
36. 36. Folstein MR, Folstein S, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 128-198.
37. 37. Coblentz JM, Mattis S, Zingesser LH, Kasoff SS, Wisneiwski HM, Katzman R. Presenile dementia: Clinical evaluation of cerebrospinal fluid dynamic. Arch Neurol 1973; 29: 299-308.
38. 38. Kukull WA, Larson EB, Bowen JB, McCormick WC, Teri L, Pfanschmidt M, et al. Solvent exposure as a risk of Alzheimer's disease: A case control study. Am J Epidemiol 1995; 141: 1059-1071.
39. 39. Emi W, Wu LL, Robertson MA, Myerson RL, Hegele RA, Williams RR, et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 1988; 3: 373-379.
40. 40. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990; 31: 545-548.
41. 41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
42. 42. McCormick WC, Kukull WA, vanBelle G, Bowen JD, Teri L, Larson EB. Symptom patterns and comorbidity in the early stages of Alzheimer's disease. J Am Geriatr Soc 1994; 42: 517-521.